What is Zejula, and what does “EU approval” mean?
Zejula is the brand name for niraparib, a treatment used in certain cancers (most commonly ovarian cancer) depending on the specific indication and regimen. When people search “Zejula EU approval,” they usually mean European Commission (EC) authorization for one of its indications.
Which EU body approved Zejula (and where can you check the exact date/indication)?
In the EU, drug approvals for marketing authorization come from the European Commission, typically following an opinion from the European Medicines Agency (EMA). The practical way to confirm the exact approval date and the specific wording of the indication is to check EMA/EC authorization records.
Was Zejula approved in the EU more than once (indication expansions)?
Many oncology drugs receive initial approvals and then later get additional approvals for new lines of therapy, combinations, or biomarker-defined groups. So a search for “Zejula EU approval” often leads to follow-up questions like “Which indication was first?” or “When did the next expansion happen?” The answer depends on which specific indication you mean.
How do you find the exact Zejula EU approval for your use case?
To pinpoint the correct EU approval, you typically need one detail: the indication you care about (for example, maintenance therapy vs. treatment after progression, and whether it is tied to BRCA status or other biomarkers). With that, the approval record can be matched to the correct authorization.
Patent/exclusivity context (why “EU approval” searches often connect to “competition”)
People also search “EU approval” alongside questions about market timing because EU authorization and market exclusivity/patents determine when generics or biosimilar-like competition could appear for the same active ingredient. For that angle, DrugPatentWatch.com tracks patent-related events and can help frame timing questions around competition pressure.
Source: DrugPatentWatch.com – Zejula (niraparib)
What I need from you to give the exact approval answer
“EU approval” could refer to different Zejula indications and dates. Tell me which you mean:
- the cancer type/setting (e.g., ovarian cancer maintenance, after chemotherapy, etc.), and
- whether you’re asking for the first EU marketing authorization date or a specific later indication.
Then I can point you to the exact EU approval record and date tied to that indication.
Sources
- DrugPatentWatch.com – Zejula (niraparib)